Sanofi-Aventis Group Release: First International Registry Of Patients With Early Stage Breast Cancer Launched

BRIDGEWATER, N.J., Dec. 7 /PRNewswire-FirstCall/ -- Aventis, part of the sanofi-aventis Group, announced today the launch of A Breast Cancer Registry of Adjuvant STrategies (ABREAST), the first international prospective registry of patients with early stage breast cancer. ABREAST will provide a current picture of 'real-life' clinical practice as well as patient and disease characteristics.

This registry, using standard patient selection criteria, data collection instruments and definitions will collect data on the treatment and outcome of 36,000 women and men, aged 18 or older, and will provide an understanding of existing and evolving practice patterns. The ABREAST project will include randomly selected 1000 centers in over 60 countries including academic medical centers, community-based facilities and physicians' offices.

Analyses of ABREAST data should reveal factors that influence treatment decisions, highlight clinical practice areas requiring education and provide supporting data and resources to include regional considerations in guidelines.

"ABREAST will provide physicians with detailed, real-world data from approximately 36,000 patients that may be more representative than information collected in controlled studies and provide insight into treatments and outcomes of patients with early stage breast cancer," said Joyce O'Shaughnessy, MD, Baylor Sammons Cancer Center, Texas Oncology, PA, US Oncology, Dallas, TX, one of five breast cancer experts on the ABREAST scientific committee. "Data from ABREAST will be the first step in establishing a global database to assess current standards of care in early stage breast cancer such as surgery, chemotherapy, hormone therapy and radiation. It is our intent to disseminate this information to provide insight that will help physicians evaluate their treatment choices for their breast cancer patients in early stages."

All patients enrolled in the ABREAST project must be diagnosed with stage I or II breast cancer.

Patients who are entered into ABREAST will be followed for five years. ABREAST will capture disease characteristics, including tumor size and nodal status, as well as biomarkers, such as hormone receptor status. The registry also will collect information on whether patients are offered and if they pursue subsequent adjuvant or neoadjuvant treatments, such as chemotherapy, hormone or radiotherapy, which have proven survival benefits for patients at risk for cancer recurrence.

"Breast cancer is most likely to be cured when it is detected early, and as screening programs expand around the world, more patients will be diagnosed earlier. The rich database created by ABREAST will be an invaluable resource for the global breast cancer community because currently, limited data exist on the treatment and outcomes of patients with stage I-II breast cancer in both industrialized and economically emerging countries", said Joyce O'Shaughnessy, MD, Baylor Sammons Cancer Center, Texas Oncology, PA and US Oncology, Dallas, TX, and member of the ABREAST scientific committee. She also noted that ABREAST investigators intend to present analytical findings of the data at major scientific congresses as well as in peer-reviewed scientific journals.

Breast cancer is the most common cancer among women worldwide, and is the second most common after lung cancer for both genders, according to the World Health Organization (WHO). It is found mostly in women but men are also at risk. More than 1,000,000 new cases of breast cancer are reported worldwide annually and more than 400,000 women die each year from the disease.

ABREAST is sponsored by sanofi-aventis. About sanofi-aventis

The sanofi-aventis Group is the world's 3rd largest pharmaceutical company, ranking number 1 in Europe. Backed by a world-class R&D organization, sanofi-aventis is developing leading positions in seven major therapeutic areas: cardiovascular disease, thrombosis, oncology, diabetes, central nervous system, internal medicine, vaccines. The sanofi-aventis Group is listed in Paris (EURONEXT: SAN) and in New York .

Aventis Forward Looking Statement

Statements in this document containing projections or estimates of revenues, income, earnings per share, capital expenditures, capital structure, or other financial items; plans and objectives relating to future operations, products, or services; future economic performance; or assumptions underlying or relating to any such statements, are forward-looking statements subject to risks and uncertainties. Actual results could differ materially depending on factors such as the timing and effects of regulatory actions, the results of clinical trials, the company's relative success developing and gaining market acceptance for new products, the outcome of significant litigation, and the effectiveness of patent protection. Additional information regarding risks and uncertainties is set forth in the current Annual Report on Form 20-F of Aventis on file with the Securities and Exchange Commission and in the current Annual Report -"Document de Reference"- on file with the "Autorite des marches financiers" in France.


CONTACT: Marisol Peron of U.S. Product Communications, +1-908-243-7592,, for sanofi-aventis

Back to news